We are live on ! Find out more
EGRX

Eagle Pharmaceuticals, Inc.
EGRX

Delisted

EGRX was delisted on the 2nd of October, 2024.

Back to rankings

120 hedge funds and large institutions have $1.08B invested in Eagle Pharmaceuticals, Inc. in 2015 Q2 according to their latest regulatory filings, with 62 funds opening new positions, 29 increasing their positions, 26 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

520% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 10

121% more capital invested

Capital invested by funds: $489M → $1.08B (+$592M)

76% more funds holding

Funds holding: 68 → 120 (+52)

20% more funds holding in top 10

Funds holding in top 10: 5 → 6 (+1)

12% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 26

75% less call options, than puts

Call options by funds: $1.36M | Put options by funds: $5.5M

Holders
120
Holders Change
+52
Holders Change %
+76.47%
% of All Funds
3.23%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.16%
New
62
Increased
29
Reduced
26
Closed
10
Calls
$1.36M
Puts
$5.5M
Net Calls
-$4.14M
Net Calls Change
-$4.14M

Top Buyers

Rank Fund Capital Flow
1
RIM
Ranger Investment Management
Texas
+$29.7M
2
CCM
Consonance Capital Management
New York
+$29.1M
3
State Street
State Street
Massachusetts
+$28.1M
4
PA
Perceptive Advisors
New York
+$14.4M
5
BFA
BlackRock Fund Advisors
California
+$12.8M

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$27.1M
2
GE
General Electric
Ohio
-$25.2M
3
Morgan Stanley
Morgan Stanley
New York
-$11.2M
4
PWAM
Park West Asset Management
California
-$7.9M
5
EI
EAM Investors
California
-$5.02M
Name Holding Trade Value Shares
Change 		Change in
Stake
RFC
26
Russell Frank Company
Washington
$4.14M +$394K +6,046 +13%
OM
27
Opaleye Management
Massachusetts
$4.04M +$3.26M +50,000 New
TCM
28
Timpani Capital Management
Wisconsin
$4M +$3.22M +49,454 New
ARTA
29
A.R.T. Advisors
New York
$3.85M -$1.38M -21,142 -31%
Marshall Wace
30
Marshall Wace
United Kingdom
$3.84M +$3.09M +47,509 New
AL
31
AJO LP
Pennsylvania
$3.83M +$3.08M +47,340 New
William Blair & Company
32
William Blair & Company
Illinois
$3.54M -$3.67M -56,405 -56%
Two Sigma Investments
33
Two Sigma Investments
New York
$3.42M -$305K -4,679 -10%
PI
34
Putnam Investments
Massachusetts
$3.17M +$2.55M +39,200 New
GH
35
GAM Holding
Switzerland
$2.96M +$2.38M +36,600 New
DCM
36
Driehaus Capital Management
Illinois
$2.88M +$2.32M +35,590 New
TC
37
TFS Capital
Pennsylvania
$2.82M +$789K +12,108 +53%
Invesco
38
Invesco
Georgia
$2.82M +$2.17M +33,253 +2,078%
BCM
39
Bridgeway Capital Management
Texas
$2.6M +$9.77K +150 +0.5%
TCIM
40
TIAA CREF Investment Management
New York
$2.58M +$2.08M +31,932 New
BA
41
BlackRock Advisors
Delaware
$2.45M +$1.97M +30,268 New
BIM
42
BlackRock Investment Management
Delaware
$2.37M +$1.87M +28,669 +4,692%
Citadel Advisors
43
Citadel Advisors
Florida
$2.29M +$1.43M +21,893 +342%
SAM
44
Sectoral Asset Management
Quebec, Canada
$2.28M +$394K +6,046 +27%
AQR Capital Management
45
AQR Capital Management
Connecticut
$2.21M +$1.23M +18,872 +222%
PP
46
PDT Partners
New York
$2.14M +$124K +1,907 +8%
Northern Trust
47
Northern Trust
Illinois
$2.1M +$1.03M +15,820 +156%
Morgan Stanley
48
Morgan Stanley
New York
$1.96M -$11.2M -172,365 -88%
SLG
49
Stanley-Laman Group
Pennsylvania
$1.94M – – –
Renaissance Technologies
50
Renaissance Technologies
New York
$1.89M -$2.38M -36,500 -61%
1
2
3 4 5

EGRX Hedge Fund Activity: Q2 2015 in Review

120 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q2 2015, worth a combined $1.08B — up 121% from $489M a quarter earlier.

Buyers outnumbered sellers: 62 funds opened new EGRX positions and 10 closed out — a net gain of 52 holders — while 29 added to existing stakes and 26 trimmed.

The largest buyer was Ranger Investment Management, opening a new position worth an estimated $29.7M. The largest seller was Cormorant Asset Management, cutting an estimated $27.1M.

  • 120 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q2 2015, up from 68 in Q1 2015.
  • Funds reported $1.08B of Eagle Pharmaceuticals, Inc. stock for Q2 2015, up 121% quarter-over-quarter.
  • 62 funds opened new Eagle Pharmaceuticals, Inc. positions in Q2 2015 and 10 closed out, a net change of +52 holders.
  • The largest Eagle Pharmaceuticals, Inc. buyer in Q2 2015 was Ranger Investment Management, an estimated $29.7M added.
  • The largest Eagle Pharmaceuticals, Inc. seller in Q2 2015 was Cormorant Asset Management, an estimated $27.1M sold.

Based on aggregated 13F filings for Q2 2015.